GlaxoSmithKline Sees Unusually High Options Volume (GSK)

GlaxoSmithKline plc (NYSE:GSK) was the recipient of unusually large options trading on Tuesday. Traders bought 32,352 put options on the company. This represents an increase of approximately 2,217% compared to the typical daily volume of 1,396 put options.

GlaxoSmithKline (NYSE GSK) opened at $36.17 on Friday. GlaxoSmithKline has a 52 week low of $34.52 and a 52 week high of $44.53. The company has a quick ratio of 0.44, a current ratio of 0.64 and a debt-to-equity ratio of 2.96. The stock has a market capitalization of $89,230.00, a price-to-earnings ratio of 42.06, a PEG ratio of 2.31 and a beta of 0.98.

GlaxoSmithKline (NYSE:GSK) last issued its quarterly earnings results on Wednesday, February 7th. The pharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.69 by $0.03. GlaxoSmithKline had a return on equity of 115.30% and a net margin of 7.79%. The company had revenue of $10.14 billion for the quarter, compared to analyst estimates of $9.89 billion. sell-side analysts expect that GlaxoSmithKline will post 2.96 earnings per share for the current year.

A number of research firms have commented on GSK. JPMorgan Chase & Co. restated a “neutral” rating on shares of GlaxoSmithKline in a research note on Monday. ValuEngine lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Zacks Investment Research lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Wednesday, January 17th. Barclays upgraded GlaxoSmithKline from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 16th. Finally, UBS Group restated a “buy” rating on shares of GlaxoSmithKline in a research note on Monday, January 15th. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $38.57.

Several institutional investors and hedge funds have recently modified their holdings of the company. 1st Global Advisors Inc. increased its stake in shares of GlaxoSmithKline by 0.4% in the 2nd quarter. 1st Global Advisors Inc. now owns 5,271 shares of the pharmaceutical company’s stock valued at $227,000 after purchasing an additional 19 shares during the last quarter. Quadrant Capital Group LLC boosted its holdings in shares of GlaxoSmithKline by 3.5% during the 2nd quarter. Quadrant Capital Group LLC now owns 4,345 shares of the pharmaceutical company’s stock valued at $162,000 after acquiring an additional 148 shares in the last quarter. High Falls Advisors Inc boosted its holdings in shares of GlaxoSmithKline by 4.9% during the 2nd quarter. High Falls Advisors Inc now owns 8,212 shares of the pharmaceutical company’s stock valued at $354,000 after acquiring an additional 384 shares in the last quarter. Laurel Wealth Advisors Inc. boosted its holdings in shares of GlaxoSmithKline by 2.6% during the 2nd quarter. Laurel Wealth Advisors Inc. now owns 27,757 shares of the pharmaceutical company’s stock valued at $1,196,000 after acquiring an additional 697 shares in the last quarter. Finally, Advisory Services Network LLC boosted its holdings in shares of GlaxoSmithKline by 24.2% during the 2nd quarter. Advisory Services Network LLC now owns 4,047 shares of the pharmaceutical company’s stock valued at $175,000 after acquiring an additional 788 shares in the last quarter. Institutional investors own 9.66% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “GlaxoSmithKline Sees Unusually High Options Volume (GSK)” was first posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/02/09/glaxosmithkline-sees-unusually-high-options-volume-gsk.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply